Pyxis Oncology’s (PYXS) “Buy” Rating Reiterated at HC Wainwright

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $5.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 371.70% from the stock’s previous close.

Several other research analysts have also commented on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $9.20.

Pyxis Oncology Price Performance

Shares of PYXS stock opened at $1.06 on Wednesday. The firm has a market cap of $63.03 million, a P/E ratio of -1.03 and a beta of 1.11. Pyxis Oncology has a 1-year low of $0.99 and a 1-year high of $6.18. The firm’s 50-day simple moving average is $1.35 and its 200-day simple moving average is $2.40.

Institutional Trading of Pyxis Oncology

A number of hedge funds have recently made changes to their positions in the stock. Ridgeback Capital Investments L.P. acquired a new stake in shares of Pyxis Oncology during the fourth quarter worth approximately $560,000. ProShare Advisors LLC acquired a new stake in shares of Pyxis Oncology during the fourth quarter worth approximately $26,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pyxis Oncology during the fourth quarter worth approximately $228,000. Millennium Management LLC grew its position in shares of Pyxis Oncology by 53.8% during the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company’s stock worth $4,650,000 after buying an additional 1,043,228 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Pyxis Oncology by 57.2% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company’s stock worth $939,000 after buying an additional 219,100 shares in the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.